EZH2 and hematopoietic and lymphoid system neoplasm: Moreover, in blood cancers, inactivating mutations of EZH2 with TET2 have been observed in patients with myelodysplastic disorders, while in vivo deletion of EZH2 could increase the expression of “Myc module” genes and lead to myelodysplastic phenotypes.